

Australia-based Bionomics appoints new President and Chief Executive Officer

15 December 2022 | News

Experienced biotech executive Spyridon Papapetropoulos to lead the next phase of growth

Australia's Bionomics has appointed Spyridon "Spyros" Papapetropoulos, M.D. as President and Chief Executive Officer (CEO). Errol B. De Souza, Ph.D., who has been serving as Bionomics' Executive Chairman since November 2018, will continue in his role through 31 December 2022 to ensure a seamless transition, and will resume the role of Non-Executive Chairman of the Board of Directors effective 1 January 2023.

Spyros is an experienced biopharmaceutical executive, a recognised neuroscientist/neurologist, and change agent with a 25-year career focused on CNS disorders.

He held various positions of increasing responsibility at CNS-focused startup/small, medium specialty and large biopharma companies. Since 2020, he has been the Chief Medical Officer of Vigil Neuroscience Inc, a Nasdaq-listed biopharmaceutical company developing a pipeline of neuroimmune targeted therapeutics for the treatment of neurodegenerative disorders.

Prior to joining Vigil, he served as Chief Development Officer, and SVP, Head of Development at Acadia Pharmaceuticals Inc., CEO at SwanBio Therapeutics, and EVP of Research & Development and Chief Medical Officer at Cavion. Before Cavion, he held senior/executive positions at Biogen Inc., Allergan plc, Pfizer Inc., and Teva Pharmaceuticals Inc.